Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 243 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Karagiannis, Asterios [Clear All Filters]
PCI and stable coronary heart disease--COURAGE to change our minds?.
Curr Vasc Pharmacol. 5(3), 173-4.
(2007). Pheochromocytoma: an update on genetics and management..
Endocr Relat Cancer. 14(4), 935-56.
(2007). Prevalence of vascular disease in metabolic syndrome using three proposed definitions..
Int J Cardiol. 117(2), 204-10.
(2007). The role of endocannabinoid system blockade in the treatment of the metabolic syndrome..
J Clin Pharmacol. 47(5), 642-52.
(2007). The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?.
Expert Opin Ther Targets. 11(2), 191-205.
(2007). Serum uric acid as an independent predictor of early death after acute stroke..
Circ J. 71(7), 1120-7.
(2007). Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients..
Open Cardiovasc Med J. 1, 8-14.
(2007). Statins and regression of coronary atherosclerosis..
JAMA. 297(20), 2197; author reply 2197.
(2007). Statins and renal function. Is the compound and dose making a difference?.
Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
(2007). Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures..
Curr Drug Targets. 8(8), 942-51.
(2007). Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster?.
Expert Opin Investig Drugs. 17(7), 969-72.
(2008). Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?.
Expert Opin Investig Drugs. 17(4), 445-9.
(2008). CORONA, statins, and heart failure: who lost the crown?.
Angiology. 59(1), 5-8.
(2008). Do we need to consider inflammatory markers when we treat atherosclerotic disease?.
Atherosclerosis. 200(1), 1-12.
(2008). Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes..
Acta Diabetol. 45(1), 23-30.
(2008). Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients..
Am J Cardiol. 101(4), 483-5.
(2008). Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia..
Am J Cardiol. 101(11), 1679-80.
(2008). Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study..
Curr Med Res Opin. 24(6), 1593-9.
(2008). Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?.
Expert Opin Ther Targets. 12(7), 809-20.
(2008). Has the time come for a new definition of microalbuminuria?.
Curr Vasc Pharmacol. 6(2), 81-3.
(2008). High density lipoprotein cholesterol and statin trials..
Curr Med Chem. 15(22), 2265-70.
(2008). Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas..
Endocr Relat Cancer. 15(3), 693-700.
(2008). Omega-3 fatty acids: how can they be used in secondary prevention?.
Curr Atheroscler Rep. 10(6), 510-7.
(2008). Preventing macrovascular complications of diabetes: where do we stand with glycemic control?.
Expert Opin Investig Drugs. 17(12), 1777-9.
(2008). Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?.
Expert Opin Pharmacother. 9(9), 1437-40.
(2008).